<code id='B2BA38479E'></code><style id='B2BA38479E'></style>
    • <acronym id='B2BA38479E'></acronym>
      <center id='B2BA38479E'><center id='B2BA38479E'><tfoot id='B2BA38479E'></tfoot></center><abbr id='B2BA38479E'><dir id='B2BA38479E'><tfoot id='B2BA38479E'></tfoot><noframes id='B2BA38479E'>

    • <optgroup id='B2BA38479E'><strike id='B2BA38479E'><sup id='B2BA38479E'></sup></strike><code id='B2BA38479E'></code></optgroup>
        1. <b id='B2BA38479E'><label id='B2BA38479E'><select id='B2BA38479E'><dt id='B2BA38479E'><span id='B2BA38479E'></span></dt></select></label></b><u id='B2BA38479E'></u>
          <i id='B2BA38479E'><strike id='B2BA38479E'><tt id='B2BA38479E'><pre id='B2BA38479E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:24275
          3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT
          Adobe

          Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

          The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

          advertisement

          The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          At Orexo, a ‘turning point’ for everything but digital health
          At Orexo, a ‘turning point’ for everything but digital health

          AdobeMosteverythingislookingupforOrexo,thecompanyreportedonitssecondquarterearningscallonTuesday.Tha

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

          DarronCummings/APThebenefitsandrisksofEliLilly’streatmentforAlzheimer’sdiseasewereconfirmedindetaile